Literature DB >> 22532986

Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease.

Kee Kiat Yeo1, Andrew W Walter, Robin E Miller, Josep Dalmau.   

Abstract

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological syndrome associated with lung cancer, breast adenocarcinoma,ovarian adenocarcinoma, and Hodgkin disease. It is rarely seen in pediatrics. We report a case of a 10-year-old boy with a 2-year prodrome that led to a diagnosis of PCD in association with stage IV Hodgkin disease. He received radiation and chemotherapy for his Hodgkin disease with resolution of his lymphoma. Based on promising data in adults on the efficacy of rituximab over other immuno suppressive agents in paraneoplastic disorders, he was treated with rituximab with marked improvement of the cerebellar syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532986     DOI: 10.1002/pbc.23314

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

Review 1.  Treatment of Cerebellar Ataxia in the Context of Systemic Diseases.

Authors:  Malcolm Proudfoot; Alastair Wilkins
Journal:  Curr Treat Options Neurol       Date:  2017-11-25       Impact factor: 3.598

2.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.